RxDoctor Payments Data

Michele Miano, MD

Ophthalmology · Cherry Hill, NJNPI 1245269919

Payments from drug & device makers

$1,793in general payments, 2019–2025

Across 20 payments — averaging $89.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$405
  • Rxsight Inc$315
  • Alcon$310
  • Johnson & Johnson Surgical Vision, Inc.$289
  • AbbVie$231
  • Lensar, Inc.$159
  • plus $85 from 2 others

What the payments were for

  • Food & beverage$1,77599%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,793 in reported general payments places this provider in the 55th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$364,303
Medicare patients
991
Services billed
3,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine82$91,247
Cyclosporine30$27,844
LumiganBimatoprost40$21,181
CombiganBrimonidine Tartrate/Timolol33$10,944
MieboPerfluorohexyloctane/Pf11$8,245
Brimonidine Tartrate56$6,148
Travoprost42$5,422
IlevroNepafenac13$4,820
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat200$4,473
Latanoprost327$4,307
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$3,745
Timolol Maleate143$2,856
SimbrinzaBrinzolamide/Brimonidine Tart11$2,033
Prednisolone Acetate51$1,929
Dorzolamide Hcl41$1,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$231$123,372155 claims
Bausch & Lomb Americas Inc.Miebo$405$8,24511 claims
AlconSimbrinza$310$2,03311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →